The case for & against
Bull & Bear analysis
Bullish
Niagen Bioscience, Inc. (NASDAQ: NAGE) is a leading company in the health and wellness sector, primarily focused on the development and commercialization of nicotinamide riboside and other NAD-related products. The company has carved out a niche in the healthy-aging supplement market with its flagship product, Tru Niagen®. Recently, Niagen has sought to expand its reach into pharmaceuticals and skincare, leveraging its expertise in NAD biology. As consumer interest in NAD-related health solutions grows, Niagen is well-positioned to benefit from this trend.
Bull says
- ↑Q2 revenue reached $29.8 M (+2% YoY), Tru Niagen $24.2 M (+6%).
- ↑E-commerce sales grew 23% YoY to $20.5 M; 10–15% growth guide.
- ↑Retail footprint expanded to ~300 GNC and Sam’s Club outlets.
- ↑NB4168 pharma program carries $200–400 M NPV potential.
- ↑NAD supplement market exceeds $2 B annually, driving sustained demand.
- ↑Strong profitability profile, high earnings yield, and low rate sensitivity.
Bear says
- ↓Stock volatility is extremely high, deterring risk-averse investors.
- ↓Negative analyst revisions highlight weaker-than-expected earnings outlook.
- ↓Competitive NMN products could pressure market share and margins.
- ↓Operating expenses rose to 34% of revenue in Q2 from 26.4%.
- ↓No dividend and weak book-to-price valuations weigh on returns.
- ↓Downward earnings tweaks and lack of analyst confidence hamper sentiment.
Investment themes with NAGE
Others↑ +0.32%
Miscellaneous or uncategorized companies
ATAI · SVIX · SVXY
Earnings Call · Q3 2024 · Mgmt. Guidance
Updated 11-09-2025bullish
Transcript signals
Bull points
- in the third quarter, we achieved record results on both our top line and our bottom line with $25.6 million in revenue, a 31% increase year over year, and net income of $1.9 million. This quarter also marks our sixth consecutive quarter of positive adjusted EBITDA reaching $2.9 million. And we generated total positive cash flow of $5.1 million. We ended the quarter with $32.4 million in cash and no debt.
- The record sales this quarter were driven primarily by growth in our e-commerce business, as well as the Niagen ingredient business, which included this quarter initial sales of our pharmaceutical grade Niagen to selected clinics debuting Niagen Plus or Niagen IV.
- As we continue to represent the gold standard in scientific and professional superiority in the NAD industry, our marketing efforts will continue to focus on optimizing brand and product awareness through influencer and social media marketing, as well as optimizing conversion and retention strategy to drive long-term customer value.
Bear points
- While this had an impact on the third quarter with a decline in sales year over year and may have an impact on our sales to Watson's for the full year, we are actively collaborating with them on different marketing initiatives to close the year and into next year, including better leveraging YouTube and social media messaging, KOL and consumer testimonials to promote new customer acquisition and utilizing personalized messaging to retain newly acquired customers.
Read full transcript analysis ›